Triptorelin
Also known as: Triptorelin pamoate, Triptorelin acetate, Triptorelin embonate, D-Trp6-LHRH, Decapeptyl, Triptodur, GnRH agonist triptorelin
Gonadotropin-releasing hormone (GnRH) agonist / Luteinizing hormone-releasing hormone (LHRH) agonist; synthetic decapeptide
What it is
Triptorelin is a hormone-suppressing peptide FDA-approved for central precocious puberty, prostate cancer, and breast cancer treatment. It works by initially stimulating and then shutting down the production of sex hormones from the pituitary. Prescription-only; approved for multiple indications; also used in gender medicine for puberty suppression.
The scientific side
Triptorelin is a synthetic GnRH analogue in which glycine-6 of the native GnRH molecule is substituted with D-tryptophan, increasing resistance to enzymatic breakdown and affinity for LHRH receptors. This substitution confers a superagonistic effect and a biological half-life approximately 10-fold longer than the native hormone after subcutaneous injection. Upon initial administration, triptorelin stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, causing a transient "flare-up" in testosterone or estrogen levels; with continued exposure, it triggers receptor down-regulation (decrease in receptor synthesis), resulting in sustained suppression of LH, FSH, and downstream sex steroids (PMID 22691297, PMID 16302716). In prostate cancer patients, this mechanism initially surges LH and testosterone, followed by suppression — leading to medical castration. In central precocious puberty (CPP), sustained pituitary-gonadal axis suppression halts premature pubertal development. Triptorelin also binds LHRH receptors overexpressed on certain cancer cells (e.g., triple-negative breast cancer, GnRH-receptor-positive breast cancer cells), enabling targeted drug delivery applications.
Class: Gonadotropin-releasing hormone (GnRH) agonist / Luteinizing hormone-releasing hormone (LHRH) agonist; synthetic decapeptide
Legal & regulatory status
Approved (FDA) for central precocious puberty (Triptodur cited, PMID: 29294465); approved in association with tamoxifen or aromatase inhibitor and with fulvestrant and palbociclib in premenopausal women with hormone…
GnRH analogs including triptorelin are on the World Anti-Doping Agency (WADA) list of prohibited substances
Not stated in reviewed literature — requires manual verification
What it's studied for
- Central precocious puberty (CPP) — treatment and pubertal suppression Human RCT
- Phase 3 open-label trial in 66 Chinese children with CPP: triptorelin pamoate 22.5 mg 6-month formulation administered twice (day 1 and month 6). At month 6, 100% had LH suppression; 98.5% maintained suppression at month 12. 19.7% experienced drug-related TEAEs; no grade ≥3 TEAEs. PMID 39412628 Yu X et al. Advances in therapy (2024)
- Multicenter, 12-month trial in 64 CPP children treated with triptorelin 11.25 mg every 3 months. GnRH-stimulated peak LH ≤3 IU/L achieved in 85%, 97%, and 95% at months 3, 6, and 12, respectively. Well tolerated; severe injection pain in one instance. PMID 16382000 Carel JC et al. European journal of endocrinology (2006)
- Meta-analysis of 153 CPP children (140 girls, 13 boys) treated with triptorelin 11.25 mg 3-month formulation. Suppressed LH peak (≤3 IU/L) in 87.6% at 3 months and 92.8% at 6 months. PMID 28334719 Durand A et al. Hormone research in paediatrics (2017)
- Phase 3, international, non-comparative study in 44 treatment-naïve CPP patients (39 girls, 5 boys). 93.2% showed prepubertal LH levels at month 6 with 22.5 mg 6-month formulation; suppression exceeded 93% at each time point. No unexpected drug-related adverse events. PMID 26887034 Klein K et al. Journal of pediatric endocrinology & metabolism (2016)
- 42 idiopathic CPP patients treated with 6-month triptorelin pamoate formulation for ≥12 months. Basal LH suppressed to <1.0 IU/L; PAH SDS improved during treatment. No adverse effects observed. PMID 36875449 Yoo E et al. Frontiers in endocrinology (2023)
- Retrospective study of 106 girls with CPP: triptorelin 11.25 mg 3-month depot vs. 3.75 mg 1-month depot. Both formulations were comparably efficacious in suppressing LH and inhibiting bone maturation. PMID 34463062 Chung LY et al. Journal of Korean medical science (2021)
- Phase 3, multicenter, open-label study of triptorelin pamoate 11.25 mg every 3 months in CPP. Suppressed LH response (≤3 IU/L) in 83.8% at month 3 and 86.5% at month 6. Adverse events mild to moderate. PMID 27603324 Zenaty D et al. Hormone research in paediatrics (2016)
- Retrospective comparison of triptorelin acetate 3.75 mg/month vs. triptorelin pamoate 3.75 mg/4 weeks in 60 girls with idiopathic CPP. Both formulations produced good response; triptorelin pamoate had more effective LH peak reduction, while triptorelin acetate was more effective in reducing ovarian volume. PMID 31441342 Lasorella S et al. Gynecological endocrinology (2020)
- Prostate cancer — androgen deprivation therapy (ADT) Human RCT
- Phase 3, open-label, multicenter study in 120 advanced prostate cancer patients: two IM injections of triptorelin embonate 22.5 mg at 24-week intervals. 97.5% achieved castrate testosterone (≤50 ng/dL) by day 29; 93.0% maintained castration months 2–12. Most common drug-related adverse event: hot flushes (71.7%). PMID 19888782 Lundström EA et al. Clinical drug investigation (2009)
- Pooled retrospective analysis of 920 male prostate cancer patients in 9 prospective studies with 1-, 3-, and 6-month triptorelin SR formulations. After 1, 3, 6, 9, and 12 months: 79%, 92%, 93%, 90%, and 91% of patients reached testosterone <20 ng/dL, respectively. PMID 28028737 Breul J et al. Advances in therapy (2017)
- Systematic review of 16 direct comparative trials of GnRH agonists (goserelin, triptorelin, leuprorelin) in prostate cancer. Studies did not show major differences in testosterone or PSA reduction; insufficient evidence to declare equivalence. PMID 29438592 Bolton EM, Lynch T. BJU international (2018)
- Cost-effectiveness analysis (Iran): triptorelin yielded 6.658 QALYs at mean cost of $18,124.75 over 20 years for metastatic prostate cancer. Goserelin was the most cost-effective option in this model. PMID 38663058 Rezaee M et al. Value in health regional issues (2024)
- Endometriosis — pain reduction and hormonal suppression Human RCT
- Phase 3 RCT in 300 Chinese women with endometriosis: triptorelin pamoate 3-month (15 mg/12 weeks) vs. triptorelin acetate 1-month (3.75 mg/4 weeks) for 6 months. >98% in both groups achieved estradiol castration levels at 12 weeks. Both equally effective for pain reduction; no new safety concerns. PMID 35947347 Li X et al. Advances in therapy (2022)
- Multicenter prospective non-interventional study in 384 Chinese women with deep infiltrating endometriosis (DIE): triptorelin 3.75 mg every 28 days for up to 24 weeks post-conservative surgery. Cumulative improvement rates: pelvic pain 74.4%, dysmenorrhea 83.6%. 24-month cumulative recurrence rate 22.2%. Well tolerated PMID 35119037 Zhu L et al. Medicine (2022)
- Clinical trial comparing triptorelin acetate (3.75 mg/4 weeks, SC) vs. oral dienogest for 16 weeks in women with adenomyosis. Triptorelin was more effective in controlling menorrhagia and reducing uterine volume; both equivalent for pelvic pain. PMID 25990480 Fawzy M, Mesbah Y. Archives of gynecology and obstetrics (2015)
- Breast cancer — adjuvant ovarian function suppression in hormone receptor-positive early breast cancer Human RCT
- Review: A 1-month triptorelin (Decapeptyl) formulation is approved in the EU as adjuvant treatment combined with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in premenopausal women at high risk of recurrence. Based on SOFT and TEXT studies; OFS with triptorelin added to tamoxifen PMID 29177573 Frampton JE. Drugs (2017)
- Triptorelin is FDA and EMA approved in association with tamoxifen or aromatase inhibitor (and fulvestrant/palbociclib) in premenopausal women with HR-positive breast cancer. Combination with tamoxifen and exemestane increased endocrine-deprivation symptoms. PMID 31500470 Ferraro E et al. Expert opinion on pharmacotherapy (2019)
- Gender dysphoria / puberty suppression in transgender adolescents Human observational
- Review: Triptorelin used as puberty blocker for transgender/gender-diverse adolescents with gender dysphoria. Effective in reducing psychological distress; concerns regarding side effects including slowed growth, increased BMI, and bone health risks. Italy suspended therapy in some centers citing inadequate psychologic PMID 41267605 Lacasella G et al. La Clinica terapeutica (2025)
- Review: Italian National Committee for Bioethics endorsed off-label use of triptorelin for adolescent gender dysphoria since 2018. Concerns persist regarding long-term effects on bone density, brain development, and fertility. Off-label use designation noted. PMID 40109078 Lippi M et al. La Clinica terapeutica (2025)
- Diagnosis of central precocious puberty (stimulation testing) Human observational
- Retrospective review of 662 girls: subcutaneous triptorelin stimulation produced peak LH levels similar to gonadorelin (12.8±12.1 vs. 13.9±12.8 IU/L). Triptorelin responses peaked later (up to 120 min); a 120-minute triptorelin stimulation test is a practical option for CPP diagnosis. PMID 41956123 Cho MH et al. Hormone and metabolic research (2026)
- 186 girls with thelarche; triptorelin 100 mcg/m² administered IV/IM with LH measured at baseline and 4 hours post-injection. New proposed LH threshold of 5 IU/L post-triptorelin (previously 15 IU/L) for early CPP diagnosis. PMID 39382826 Cavarzere P et al. Endocrine (2025)
- Monitoring efficacy of triptorelin depot treatment in precocious puberty Human observational
- 128 girls with precocious/early puberty; 81 received triptorelin depot 3.75 mg. Urinary FSH (UFSH) measured by ICMA from stimulated 12-hour urine samples showed AUC 0.962–0.985 for determining treatment efficacy, superior to serum peak LH (AUC 0.746). UFSH ≤5.24–6.94 IU/L at various timepoints indicated efficacy. PMID 40813175 Zhou Y et al. Archives de pediatrie (2025)
- Assisted reproductive technology (ART) / IVF — pituitary downregulation Human observational
- Retrospective cohort study of 3,186 IVF/ICSI cycles using GnRH agonist long protocol: depot triptorelin 1.25 mg vs. 1.875 mg for pituitary suppression. No significant difference in live birth rate (41.2% vs. 43.7%). Lower dose had higher LH on FSH-start day but similar outcomes. PMID 27072965 Chen X et al. Journal of Huazhong University (2016)
- Colorectal endometriosis — intestinal symptom improvement Human observational
- Clinical trial: triptorelin improves intestinal symptoms in patients with colorectal endometriosis (no further abstract text available). PMID 19944420 Ferrero S et al. International journal of gynaecology and obstetrics (2010)
- Nanoparticle-targeted drug delivery / MRI contrast agent (experimental, cancer targeting) In vitro only
- Triptorelin-conjugated PEG-coated gold nanoparticles showed 3–9-fold greater predicted adhesion to triple-negative breast cancer (TNBC) cells vs. non-tumorigenic cells in AFM experiments and MD simulations, attributed to LHRH receptor overexpression on TNBC. PMID 35929297 Uzonwanne VO et al. Biomaterials advances (2022)
- SPION@CMD@triptorelin nanoparticles showed 6.5-fold greater cellular uptake in MDA-MB-231 cancer cells vs. unconjugated SPION@CMD. No cytotoxicity observed; suitable as T2-weighted MRI contrast agent for GnRH-positive cancer. PMID 34104122 Yousefvand M et al. Contrast media & molecular imaging (2021)
Protocol
100 mcg subcutaneous injection, single one-time dose. Cycle: one-time use (no repeat cycle).
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not specified (intramuscular in related studies) | 22.5 mg (triptorelin pamoate) per injection | 12 months (two doses: day 1 and month 6) | human | Research PMID 39412628 |
| Not specified (injection) | 15 mg per injection (triptorelin pamoate 3-month) OR 3.75 mg per injection (triptorelin acetate 1-month) | 6 months | human | Research PMID 35947347 |
| Not specified (injection) | 3.75 mg once every 28 days | Up to 24 weeks | human | Research PMID 35119037 |
| Subcutaneous injection | 3.75 mg every 4 weeks (triptorelin acetate) | 16 weeks | human | Research PMID 25990480 |
| Intramuscular | 22.5 mg (triptorelin embonate) per injection | 12 months (two doses at 24-week intervals) | human | Research PMID 19888782 |
| Not specified | 1-month, 3-month, and 6-month sustained-release formulations (dose not specified per injection in abstract) | 2–12 months | human | Research PMID 28028737 |
| Intramuscular | 11.25 mg every 3 months (90 days) | 12 months | human | Research PMID 16382000 |
| Intramuscular | 11.25 mg (triptorelin pamoate) every 3 months | 6 months | human | Research PMID 27603324 |
| Not specified (injection) | 11.25 mg (3-month depot) OR 3.75 mg (1-month depot) | 12 months | human | Research PMID 34463062 |
| Not specified (injection) | 3.75 mg/month (triptorelin acetate) OR 3.75 mg/4 weeks (triptorelin pamoate) | 24 months | human | Research PMID 31441342 |
| Intramuscular | 22.5 mg per injection (administered twice at 24-week intervals) | 48 weeks | human | Research PMID 26887034 |
| Intramuscular | 11.25 mg | 3 to 6 months (per study) | human | Research PMID 28334719 |
| Not specified | 11.25 mg every 90 days | 12 months | human | Research PMID 22645436 |
| Not specified | 11.25 mg every 90 days | 2 years | human | Research PMID 16995580 |
| Injection (route not specified in abstract) | 100 mcg/m² (stimulation test dose) | Single dose (diagnostic test), LH measured at baseline and 4 hours post-injection | human | Research PMID 39382826 |
| Not specified | 3.75 mg (depot) for treatment monitoring; 100 µg (stimulation test) | 3 months of treatment; single-dose stimulation test | human | Research PMID 40813175 |
| Not specified (depot injection) | 1.25 mg or 1.875 mg (depot, one-third standard depot) | Per IVF/ICSI cycle long protocol | human | Research PMID 27072965 |
| Not specified | 22.5 mg (6-month formulation) | 12–18 months | human | Research PMID 36875449 |
| Intramuscular | 0.6 mg/kg per 28 days (three consecutive doses) | 3 doses over ~84 days | animal | Research PMID 24510211 |
| Not specified | Administration intervals ranged from 3 to 5 weeks depending on adequacy of pubertal suppression | Minimum 1-year treatment course observed | human | Research PMID 41841385 |
| subcutaneous injection | 100 mcg | single one-time dose · one-time use (no repeat cycle) | male anabolic steroid users post-cycle (PCT) | [Community] |
| subcutaneous injection | 500 mcg | single one-time dose · one-time use | male anabolic steroid users post-cycle (PCT), typically after very heavy or long suppression | [Community] |
| subcutaneous injection | 100 mcg | single one-time dose · one-time use, administered mid-cycle or at cycle end | male anabolic steroid users seeking to maintain testicular function during a long cycle | [Community] |
| intramuscular injection | 100 mcg | single one-time dose · one-time use | male anabolic steroid users post-cycle (PCT) | [Community] |
| subcutaneous injection | 100 mcg | single one-time dose, followed by standard SERMs (e.g. Nolvadex/Clomid) 2–4 weeks later · one-time shot, then SERM PCT begins after washout | male anabolic steroid users running a combined PCT protocol | [Community] |
All studies (34)
- PMID 16382000 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 19888782 Human RCT
Prostate cancer — androgen deprivation therapy (ADT) - PMID 25990480 Human RCT
Endometriosis — pain reduction and hormonal suppression - PMID 26887034 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 27603324 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 28028737 Human RCT
Prostate cancer — androgen deprivation therapy (ADT) - PMID 28334719 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 29177573 Human RCT
Breast cancer — adjuvant ovarian function suppression in hormone receptor-positive early breast canc - PMID 29438592 Human RCT
Prostate cancer — androgen deprivation therapy (ADT) - PMID 31441342 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 31500470 Human RCT
Breast cancer — adjuvant ovarian function suppression in hormone receptor-positive early breast canc - PMID 34463062 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 35119037 Human RCT
Endometriosis — pain reduction and hormonal suppression - PMID 35947347 Human RCT
Endometriosis — pain reduction and hormonal suppression - PMID 36875449 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 38663058 Human RCT
Prostate cancer — androgen deprivation therapy (ADT) - PMID 39412628 Human RCT
Central precocious puberty (CPP) — treatment and pubertal suppression - PMID 19944420 Human observational
Colorectal endometriosis — intestinal symptom improvement - PMID 27072965 Human observational
Assisted reproductive technology (ART) / IVF — pituitary downregulation - PMID 39382826 Human observational
Diagnosis of central precocious puberty (stimulation testing) - PMID 40109078 Human observational
Gender dysphoria / puberty suppression in transgender adolescents - PMID 40813175 Human observational
Monitoring efficacy of triptorelin depot treatment in precocious puberty - PMID 41267605 Human observational
Gender dysphoria / puberty suppression in transgender adolescents - PMID 41956123 Human observational
Diagnosis of central precocious puberty (stimulation testing) - PMID 16302716
- PMID 16995580
11.25 mg every 90 days Not specified (human) - PMID 22645436
11.25 mg every 90 days Not specified (human) - PMID 22691297
- PMID 24510211
0.6 mg/kg per 28 days (three consecutive doses) Intramuscular (animal) - PMID 29294465
- PMID 34104122 In vitro only
Nanoparticle-targeted drug delivery / MRI contrast agent (experimental, cancer targeting) - PMID 35929297 In vitro only
Nanoparticle-targeted drug delivery / MRI contrast agent (experimental, cancer targeting) - PMID 39757119
- PMID 41841385
Administration intervals ranged from 3 to 5 weeks depending on adequacy of pubertal suppression Not specified (human)